UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/803,960	03/19/2004	John R. White	PF497D2	8061

22195 7590 11/21/2005

HUMAN GENOME SCIENCES INC
INTELLECTUAL PROPERTY DEPT.
14200 SHADY GROVE ROAD
ROCKVILLE, MD 20850

EXAMINER	
MERTZ, PREMA MARIA	
ART UNIT	**PAPER NUMBER**
1646	

DATE MAILED: 11/21/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/803,960	WHITE ET AL.	
	Examiner	Art Unit	
	Prema M. Mertz	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) 1-4 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) 1-4 are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Election/Restriction

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

Group I. Claim 1, drawn to a chemokine comprising SEQ ID NO:1, classified in class 530, subclass 324.

Group II. Claim 1, drawn to a chemokine comprising SEQ ID NO:2, classified in class 530, subclass 324.

Group III. Claim 1, drawn to a chemokine comprising SEQ ID NO:3, classified in class 530, subclass 324.

Group IV. Claim 1, drawn to a chemokine comprising SEQ ID NO:4, classified in class 530, subclass 324.

Group V. Claim 1, drawn to a chemokine comprising SEQ ID NO:5, classified in class 530, subclass 324.

Group VI. Claim 1, drawn to a chemokine comprising SEQ ID NO:6, classified in class 530, subclass 324.

Group VII. Claim 1, drawn to a chemokine comprising SEQ ID NO:7, classified in class 530, subclass 324.

Group VIII. Claim 1, drawn to a chemokine comprising SEQ ID NO:8, classified in class 530, subclass 324.

Group IX. Claim 1, drawn to a chemokine comprising SEQ ID NO:9, classified in class 530, subclass 324.

Group X. Claim 1, drawn to a chemokine comprising SEQ ID NO:10, classified in class 530, subclass 324.

Group XI. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:1, classified in class 424, subclass 85.1.

Group XII. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:2, classified in class 424, subclass 85.1.

Group XIII. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:3, classified in class 424, subclass 85.1.

Group XIV. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:4, classified in class 424, subclass 85.1.

Group XV. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:5, classified in class 424, subclass 85.1.

Group XVI. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:6, classified in class 424, subclass 85.1.

Group XVII. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:7, classified in class 424, subclass 85.1.

Group XVIII. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:8, classified in class 424, subclass 85.1.

Group XXI. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:9, classified in class 424, subclass 85.1.

Group XX. Claims 2-4, drawn to a method of mobilizing stem cells by administering a chemokine comprising SEQ ID NO:10, classified in class 424, subclass 85.1.

Claims 1-4 embrace multiple patentably distinct embodiments. Should any one of the Groups from I-XX be elected, Applicant is required to select one polypeptide (one amino acid sequence) as set forth in SEQ ID NOS:1-10. Once one polypeptide sequence is selected, all other sequences will be withdrawn from consideration.

With respect to claims 2-4, these claims will be examined insofar as they encompass a method of treatment with the specific chemokine of that invention.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-X are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function and each has an independent utility, that is distinct for each invention which cannot be exchanged. In the instant case, the different inventions are structurally different polypeptides having a specific function. The chemokine of invention I can be used to generate antibodies specific for that chemokine, or used as a probe, or used therapeutically or diagnostically (e.g. in screening), which specific functions cannot be obtained by use of the chemokines of inventions II-X.

Inventions XI-XX are independent and distinct, each from the other, because the methods are practiced with materially different products, which are structurally and chemically different, the novelty of the inventions lying in the products being administered and not the processes. The only feature in common in the instant inventions is "the method of mobilizing stem cells", which does not constitute the special technical feature lacking from the prior art because this method can be used with a composition other than the instant products such as IL-8. Distinctness is

further shown because each of these products in each method can be made and used without any one or more of the other products. The products in the different Groups are physically, chemically and biologically distinct from each other, and if patentable would support separate patents. Furthermore, separate search terms would be required for searching the literature, eg. a search of the literature for an association of the chemokine of SEQ ID NO:1 with a method of mobilizing stem cells would not necessarily reveal art for an association of the chemokine of SEQ ID NO:2 with a method of mobilizing stem cells.

Inventions I and XI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions II and XII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions III and XIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product

as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions IV and XIV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions V and XV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions VI and XVI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions VII and XVII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions VIII and XVIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions IX and XIX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Inventions X and XX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP §

806.05(h)). In the instant case the chemokine polypeptide has an independent utility, as an antigen for antibody production.

Having shown that these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their recognized divergent subject matter as defined by MPEP § 808.02, the Examiner has *prima facie* shown a serious burden of search (see MPEP § 803). Therefore, an initial requirement of restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. § 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. § 1.48(b) and by the fee required under 37 C.F.R. § 1.17(h).

2. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter

of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (571) 272-0829.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz

Prema Mertz Ph.D., J.D.
Primary Examiner
Art Unit 1646
November 15, 2005